

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

A novel method for generating 3D constructs with branched vascular networks using multi-materials bioprinting and direct surgical anastomosis

Xin Liu, Xinhuan Wang, Liming Zhang, Lulu Sun, Heran Wang, Hao Zhao, Zhengtao Zhang, Yiming Huang, Jingjinqiu Zhang, Biaobiao Song, Chun Li, Hui Zhang, Song Li, Shu Wang, Xiongfei Zheng,* and Qi Gu**

Dr. X. Wang, J. Zhang, Prof. Q. Gu
State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, P. R. China
E-mails: qgu@ioz.ac.cn

X. Liu, Prof. Q. Gu
Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, P. R. China

L. Zhang, Dr. H. Wang, Hui Zhang, Song Li, Prof. X. Zheng
Shenyang Institute of Automation, Chinese Academy of Sciences, Shenyang 110169, P. R. China
E-mails: zhengxiongfei@sia.cn

Dr. H. Zhao, Dr. Y. Huang, Prof. S. Wang
Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190 P. R. China
E-mails: wangshu@iccas.ac.cn

Dr. L. Sun, Z. Zhang, C. Li
State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, P. R. China

B. Song
University of Science and Technology of China, Hefei, 230026, P. R. China

35 **Abstract**

36 Vessels pervade almost all body tissues, and significantly influence the
37 pathophysiology of human body. Previous attempts to establish multi-scale vascular
38 connection and function in 3D model tissues using bioprinting have had limited
39 success due to the incoordination between cell-laden materials and stability of the
40 perfusion channel. Here, we report a methodology to fabricate centimetre-scale
41 vascularized soft tissue with high viability and accuracy using multi-materials
42 bioprinting involving inks with low viscosity and a customized
43 multistage-temperature-control printer. The tissue formed was perfused with branched
44 vasculature with well-formed 3D capillary network and lumen, which would
45 potentially supply the cellular components with sufficient nutrients in the matrix.
46 Furthermore, the same methodology was applied for generating liver-like tissue with
47 the objective to fabricate and mimic a mature and functional liver tissue, with
48 increased functionality in terms of synthesis of liver specific proteins after *in vitro*
49 perfusion and *in vivo* subperitoneal transplantation in mice. Moreover, to establish
50 immediate blood perfusion, an elastic layer was printed wrapping sacrificial ink to
51 support the direct surgical anastomosis of the carotid artery to the jugular vein. Our
52 findings highlight the support extended by vasculature network in soft hydrogels
53 which helps to sustain the thick and dense cellularization in engineered tissues.

54

55

56 **Key words:** 3D printing; multivascular network; low viscosity; GelMA; hUVEC

57 **1. Introduction**

58 Three-dimensional (3D) bioprinting techniques have significantly facilitated the
59 process of fabrication of complex, heterocellular soft artificial tissues *in vitro*, which
60 combine polymeric biomaterials and cells.^[1-3] During the process of bioprinting, the
61 bioinks provide protection to the cellular component, ensuring high cell viability,
62 while also mimicking the extracellular matrix to promote bioactivity.^[4-6] Although
63 bioprinting technology has shown great potential in tissue engineering, the thickness
64 of constructed tissues was limited to several hundred micrometers due to restricted
65 oxygen and nutrient diffusion, which is integral in maintaining cell viability and
66 proliferation.^[7-8] In highly vascularized tissues, such as liver and kidney, the
67 formation of new blood vessels is essential for growth beyond the diffusion limit.^[9-10]
68 Therefore, building multi-branched perfusable vascular networks is critical to the
69 fabrication of thick tissue constructs.

70 Recent advances in 3D tissue fabrication have led to efficient bioprinting of blood
71 vessels.^[11-12] The strategies followed in these studies can be classified into two main
72 groups: (i) scaffold-based approach, and (ii) scaffold-free bioprinting of vascular
73 constructs.^[13] The first approach can be divided into three major bioprinting
74 modalities which include extrusion-based bioprinting, droplet-based bioprinting, and
75 laser-based bioprinting.^[14-15] Extrusion-based bioprinting enables fabrication of
76 macro-vascular constructs (in the order of magnitude of a few centimeters), which
77 allows printing with fugitive inks with subsequent remove for achieving a distinct
78 vascular pattern. For demonstrating this method, water-soluble sugar ink was first


79 utilized.^[16] The capillaries can be fabricated with diameters as small as 150 μm .
80 Recently, an interconnected vascular network that perfuses a centimeter-scale
81 engineered osteogenic construct was generated.^[17] The fugitive ink Pluronic F127 was
82 dissolved, and endothelial cells (ECs) were used to create a vascular bed by seeding
83 the channels. Alginate and gelatin have also been used as fugitive inks in recent
84 studies.^[18-20] However, cell-laden inks have the limitations of low cell viability (due to
85 shear damage from ink extrusion) and exhibit poor resolution of the final vascular
86 pattern formed (hundreds of micrometer voxels).^[21-22] For scaffold-free bioprinting,
87 cells encapsulated in hydrogels or decellularized matrix components could be used to
88 fabricate micro-vascular network, which otherwise relies on ECs to form new vessel
89 by physiological mechanisms.^[23] Recently, pre-vascularized spheroidal assemblies
90 with elaborate branching have been used to form vascular networks.^[24] This proves
91 that successful cellular assembly can be achieved after bioprinting by accelerated
92 vascularization, which leads to the maturation of the tissue constructs.^[14, 25]
93 Furthermore, this method can mimic tissue regeneration and development; however,
94 the vessels formed are limited in size and do not exceed the micrometer scale.^[25]

95 The bioprinted tissue constructs with blood microvessels would eventually be
96 implanted, and therefore they should be suitable for surgical anastomosis to the host
97 vasculature after implantation.^[26] Synthetic biodegradable microvessel microfluidic
98 scaffolds provide sufficient structural support and have been successfully integrated
99 with the host vasculature.^[27-28] However, soft hydrogel with vascular networks lacked
100 sufficient mechanical properties, which severely limited their utilization as a

101 load-bearing construct in tubular tissue regeneration.^[16] So far, no research effort has
102 been devoted to integration and implantation of hydrogel-based hollow vascular
103 network into host vasculature. Some efforts have used sacrificial laser-sintered for
104 constructing vascular networks, but this indirect printing method was detrimental to
105 integrated bioprinting using multi-materials.^[29] Therefore, we propose a method for
106 bioprinting vasculature structure using elastic hydrogel and cell-laden hydrogel for
107 enhanced mechanical support and biological activity. Cell-laden hydrogels may
108 potentially decrease the damage during bioprinting and solidify in a cell-friendly
109 environment, which may result in optimal cell proliferation and tissue remodeling.

110 In this study, we report the use of 3% GelMA with fibrin, as the cell-laden
111 biomaterial for extrusion and bioprinting of vascularized tissue. With gelatin as
112 fugitive inks, we printed HepG2 aggregates (HAs) with human umbilical vein
113 endothelial cells (HUVECs) and mesenchymal stem cells (MSCs) as mixture to
114 fabricate a vascularized hepatorganoid tissue (HOs), with proper endothelialization.
115 Moreover, fabrication of functional 3D printed liver tissue with normal hepatocytic
116 function was explored in this study, which involved probing liver-specific gene
117 expression and albumin secretion *in vitro*, and *in vivo* subperitoneal transplanted in
118 mice (**Figure 1A**). Furthermore, we leveraged this methodology combining 5%
119 GelMA as inner elastic inks and external elastic inks to establish surgical anastomosis
120 of the tissue, which has been rarely reported previously (Figure 1B).

121



122

123 **Figure 1.** Schematic representation of multi-materials bioprinting strategies used in

124 this study. A) Multi-materials bioprinting was performed using cell-laden inks and

125 fugitive inks to fabricate 3D hepatic tissue with proper vascularization, and

126 hepatocytic function *in vitro*. B) Multi-materials bioprinting was performed using

127 cell-laden inks, fugitive inks, and elastic inks to fabricate tissue and optimal perfusion

128 was achieved *in vivo* by direct surgical anastomosis to host vasculature (artery to

129 vein).

130

131 **2. Results and Discussion**

132 **2.1. 3D printing of vascular constructs**

133 The viscosity of bioink is one of the important factors directly influencing the process
134 of printing. When the viscosity of bioink is less (i.e. <5 Pa·s), the precision of printing
135 is low. However, when the viscosity is high, it cannot protect cells from high shear
136 stress of printing, which results in low cell survival rates.^[30] Recent studies have
137 demonstrated the suitability of GelMA hydrogels with low concentration (<5% w/v)
138 to perform as cell-based bioinks due to their high cell stability and viability.^[31-32] In
139 this study, we evaluated the viscosity of GelMA under different temperature
140 conditions (**Figure 2A**). When the GelMA concentration was 1% or 2%, its viscosity
141 was close to zero and its properties were hardly affected by temperature. However,
142 when the concentration was 3%, 4%, or 5%, its viscosity increased with the increase
143 in GelMA concentration (at 5°C), which gradually decreased with the increase in
144 temperature. However, when the temperature exceeded 25°C, the viscosity of GelMA
145 approached zero. Moreover, the addition of 0.25% fibrin had no effect on the
146 viscosity of GelMA. In order to visualize the change in viscosity of different
147 concentrations of GelMA under different temperature conditions, the viscosity data
148 were fitted to establish a three-dimensional heat map representing
149 viscosity-temperature-concentration (**Figure 2B**). The red area represents the lower
150 viscosity, and the blue area represents higher viscosity. For printability, 3% is the
151 lowest concentration of GelMA with controllable viscosity at temperatures above
152 zero.

153 GelMA is highly sensitive to temperature and light.^[33] In order to achieve high
154 precision, it is necessary to use GelMA in its printable phase and UV
155 photocrosslinking was used after completion of the printing. The printable phase and
156 UV crosslinking are two basic requirements for GelMA-based printing. The extrusion
157 phase of GelMA recorded and the printing head (BiopHead) used in this study are
158 shown in Figure 2C and Figure 2D. The gel point temperature T_0 was measured from
159 rheological tests (whereby storage modulus was equal to loss modulus). By setting the
160 primary temperature of the printing head to be slightly higher than the gel point
161 temperature T_0 , the liquid phase of GelMA was maintained. The extrusion phase of
162 GelMA was tested by adjusting the secondary temperature of the BiopHead. The
163 extrusion phase of GelMA was analyzed through a high-speed camera (Figure 2D).
164 GelMA remained in over gelation phase when the temperature was above T_0 , with the
165 extruded GelMA being distorted and irregular. GelMA remained in liquid phase when
166 the temperature was below T_0 , extruding the GelMA as a droplet at the tip of the
167 needle. When the temperature condition was set correctly, the GelMA was in printable
168 phase with the extruded GelMA being smooth with superior printing performance. As
169 shown in Figure 2C and Figure 2E, the printability of low concentration GelMA is
170 one of the goals of the experiment, and it is necessary to explore the printability of
171 low concentration GelMA. Due to the temperature and light sensitive properties of
172 GelMA, it is need to be cooled in the printhead to achieve pre-gel extrusion and
173 molding, and the physical gelatinized construction is chemically crosslinked by UV
174 lamps and cultures at 37°C to maintain shape accuracy. Therefore, the maintenance of

175 pre-gel state and purple diplomatic post-union structure are two basic requirements
176 for GelMA. First, the extrusion status of the GelMA was recorded. The printhead used
177 in the test was shown in Figure 2D. The gel point temperature T_0 (the storage modulus
178 is equal to loss modulus) was measured based on the rheological properties of bioink.
179 The liquid state of the bioink in the print silo was maintained by setting the first stage
180 temperature of the printhead slightly higher than the gel point temperature T_0 . The
181 extrusion state of the bioink was tested by adjusting the secondary temperature of the
182 printhead. The green circle in the figure represents the pre-gel state of the bioink.
183 Secondly, the maintenance effect of the construction after the purple couplet was
184 tested. When the concentration of GelMA is lower than 2%, the printing requirements
185 in the state of physical gel could be achieved by lowering the temperature. However,
186 the structure of the chemical crosslink will melt and collapse in the environment of
187 37°C, which could not meet the stability requirements. The solidification and forming
188 effect of bioink in the blue area of the test diagram is better. The above experimental
189 results show that the concentration and temperature parameters of bioink in the pink
190 range of the map are printable regions.


191 Figure 2C and Figure S1 show the BiopHead printing system used in the
192 experiment, which includes air-driven silo, electric-driven silo, primary temperature
193 control device, secondary temperature control device, and a cooling system.
194 BiopHead can achieve a temperature gradient through a two-stage temperature control
195 system, which allows the bioink in the printing silo to be in a liquid phase, and remain
196 in a printable phase in the printing needle. BiopHead can run in two extrusion modes,

197 namely the electric extrusion mode and the pneumatic extrusion mode. Electric
198 extrusion is based on volume change. In this mode, direct-current motor drives the
199 screw structure to rotate, which in turn drives the push rod (the pushing device behind
200 the syringe) to move linearly. The underlying reason for the high precision in the
201 electric extrusion mode is the precision of the screw displacement. It is difficult to
202 achieve high-precision control of the print volume when the viscosity of the bioink is
203 low, i.e., the bioink is in a thin state. Also, since the print silo of the electric extrusion
204 is smaller, the displacement of the push rod has less influence on the extrusion
205 volume. The pneumatic extrusion is based on pressure change. The pressure of the
206 rear end of the silo is changed by an air compressor (cylinder) which causes the
207 extrusion of the bioink. In the pneumatic extrusion mode, the volume extruded is
208 larger, which makes it ideal for large-volume printing. Controlling the pressure of the
209 ink is difficult, hence, printing accuracy is not guaranteed. Therefore, electric
210 extrusion is used for high-precision printing, while pneumatic extrusion is used for
211 large-scale printing involving larger volumes (e.g. <5 ml). In this study, GelMA was
212 printed using an electric drive, and the temperature control system was adjusted to
213 maintain the bioink in the gel state. The temperature of the printing silo was
214 controlled by the primary temperature control system to keep bioink in the printing
215 silo in liquid phase. The temperature of the printing needle was controlled by the
216 secondary temperature control system to maintain the bioink in a printable phase
217 suitable for printing. The extrusion state of the bioink was captured by a high-speed
218 camera. When the temperature was too low, the bioink was in over gelation phase.

219 When the temperature was too high, the bioink was in a liquid phase, and when the
220 temperature conditions were right, the bioink was in a printable phase.

221 To engineer and fabricate vascularized tissue constructs, several channel
222 configuration structures were designed. First, one straight channel within a matrix was
223 designed, which was printed with both cell-laden inks and sacrificial inks Figure 2F.
224 The cell-laden inks and fugitive inks were printed on a glass substrate with
225 dimensions of 9.6 mm × 4 mm × 2 mm. Next, photocrosslinking was achieved by
226 exposing the printed constructs to UV light for 2 mins. Then, the fugitive ink was
227 removed from the thick tissue by heating to ~37°C, whereby it undergoes a
228 gel-to-fluid transition. Furthermore, we printed several different constructs to
229 demonstrate the formation of stable vascularized tissues, including a
230 one-to-two-channeled structure Figure 2G, a one-to-four-channeled structure Figure
231 2H, a one-to-two-to-four-channeled 3D structure Figure 2I, and a
232 one-to-four-channeled 3D structure Figure 2J.

233



234

235 **Figure 2.** A) Viscosity test indicating the viscosity of GelMA and GelMA-fibrin at
 236 different concentrations. B) Three-dimensional graph indicating viscosity-temperature
 237 of GelMA and GelMA-fibrin at different concentrations. C) Visual representation of
 238 the printing system. D) Extrusion state of GelMA at different concentrations and

239 temperatures, showing liquid phase, over gelation phase, and printable phase at
240 different temperatures. E) Graphical representation of the extrusion state of GelMA at
241 different concentrations and temperatures showing the printable region. F-J)
242 Schematic illustrations and optical images of different constructs printed using
243 transparent ink along with cell-laden ink, red ink along with fugitive ink, respectively.
244 (i) schematic illustrations, (ii) top view, (iii) side view, (iv) stereogram. Scale bar
245 represents 1 mm.

246 **2.2. Characterization of GelMA-fibrin (GF) hydrogels and assessment of the**
247 **extent of formation of capillary-like network**

248 GelMA was synthesized using methacrylic anhydride (MA) to enable
249 photo-crosslinking (**Figure 3A**).^[33] To verify the percentage of functionalized
250 methacrylation groups, ¹H NMR was used to measure the extent of free amine group
251 substitution (Figure S2, Supporting Information). The results demonstrated 70%
252 methacrylation of gelatin. Previous studies have shown that GelMAs have
253 integrin-binding motifs and matrix metalloproteinase sensitive groups for cells
254 adherence and migration.^[34-35] Several successful attempts have been made in
255 generation of functional vascular networks using GelMA.^[36-38] On the other hand,
256 fibrin gels have exhibited better angiogenic sprouting and capillary lumen formation
257 with human umbilical vein endothelial cells (HUVECs).^[39-40] In order to combine the
258 optimal printing properties of GelMA and the angiogenic properties of fibrin, we used
259 cell-laden inks composed of GelMA and fibrin blends (Figure 3B). Specifically, these
260 materials form a GelMA-fibrin matrix crosslinked by dual-crosslinkers. Thrombin is


261 used to rapidly polymerize fibrinogen, whereas lithium
262 phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) as a photo-initiator for GelMA
263 crosslinking. There are three steps in the formation of the GelMA-fibrin matrix. First,
264 GelMA and fibrinogen undergo a liquid-to-gel transition as the temperature decreases.
265 Second, after UV irradiation exposure, the GelMA is rapidly crosslinked into a gel.
266 The third step involves fibrinogen polymerization into fibrin to form GelMA-fibrin
267 matrix upon submerging into thrombin solution.

268 The microstructures of the hydrogels were observed using scanning electron
269 microscopy (SEM). Micrographs of the GelMA-fibrin blends at different percentage
270 ratios after incubation at 37°C for 3 days have been presented in Figure 3C. As
271 expected, after adding fibrin, the matrix formed a crosslinked interpenetrating
272 polymer network (IPN).^[41] To ensure the appropriate biocompatibility, 3% GelMA
273 (3G) and 5% GelMA (5G) were selected as the base, and different concentrations of
274 fibrin solutions were introduced into this base solution. The SEM micrographs
275 revealed that the average size of interconnected pores increased with lowering of the
276 GelMA concentration (Figure 3C). The average size of pores increased with lowering
277 of the concentration of the GelMA used, and decreased after the addition of fibrin
278 (Figure 3E). The porous structure may facilitate nutrient diffusion and improve cell
279 survival. Besides, fibrin fibers were interpenetrating the structure of the GelMA.

280 Previous studies have shown that the presence of MSCs is crucial for the
281 formation of capillary networks.^[36] It was found that the presence of MSCs induced
282 the HUVECs to form HUVEC-networks. To assess the appropriate biocompatibility,

283 RFP-HUVECs and GFP-MSCs were co-encapsulated in a GF matrix and the extent of
284 capillary-like network formation was quantified using confocal microscopy (Figure
285 3D). Those images clearly reveal that 3% GelMA+0.25% fibrin (3GF) has higher
286 total network length and number of branch points than 5% GelMA+0.25% fibrin
287 (5GF), and 3% GelMA+1% fibrin (3G+1F), respectively (Figure 3F, G; Figure S3 and
288 Movie S1, Supporting Information). These HUVEC-networks were well established,
289 with the majority of them forming cord-like structures. Three-dimensional confocal
290 reconstructed images showed the presence of MSCs adjacent or proximal to the
291 capillary structures, suggesting that the MSCs were differentiating into perivascular
292 cells. It also indicates that 3G is more biocompatible than 5G. Moreover, 3% GelMA
293 consistently generated more robust, interconnected vascular networks with 0.25%
294 fibrin than with 1% fibrin. The formed capillary-like structures in hydrogel were
295 further investigated by SEM. The formed capillary-like structures in 3GF were found
296 to be more abundant and longer than those in 3G or 5GF, which reinforced the
297 findings of the confocal microscopy. Besides, the fiber structure of the hydrogel near
298 the capillary was partially destroyed, which may be due to the degradation of the
299 basement membrane and extracellular matrix by the secreted matrix metalloproteinase
300 (MMP). Hence, 3GF was chosen to be the cell-laden ink of choice pursued in the
301 remaining part of the study. The schematic diagram in Figure 3H presented GelMA
302 and fibrin crosslinked IPNs is based on the obtained results, and depicts HUVECs and
303 MSCs in hydrogels of different compositions.

304



305

306 **Figure 3.** Characterization of GF hydrogels and results depicting the extent of

307 capillary-like network formation. A, B) Schematic diagram depicting GelMA

308 synthesis (A), and steps involved in cell-laden ink, GF ink formation (B). C) SEM
309 images of GelMA or GelMA-fibrin hydrogels with different compositions bearing
310 RFP-HUVCEs and GFP-MSCs. Scale bar represents 10 μm . D) Representative (i-iii)
311 3D reconstruction of constructs and (iv-vi) Z-plane cross-section from confocal
312 microscopy images showing capillary-like network formation. Scale bar represents
313 100 μm . E, F) Quantitative analysis of the length (E), and branching points (F) in
314 capillary-like network. G) Graphical representation of morphological parameters of
315 HUVECs and MSCs in different percentages of GelMA-Fibrin IPN. The data are
316 presented as the mean \pm SD. *: $p < 0.1$, **: $p < 0.01$, ***: $p < 0.001$.

317

318 **2.3. Tissue perfusion culture and aggregate printing for vascular network**

319 **formation *in vitro***

320 In order to provide stable perfusion for long-term culture, we fabricated a continuous
321 flow perfusion system (**Figure 4A**; Figure S4A, Supporting Information). The system
322 includes an incubator, a built-in digital-control peristaltic pump, and a reservoir of
323 culture medium. The designed perfusion chamber (Figure 4B) consisted of three
324 components: a flow part and top and bottom parts. The first one was used for fixing
325 needles, and the top and bottom parts were made of glass which can hold the printed
326 tissue and enabled real-time observation. Before printing, the top and flow parts were
327 assembled respectively, and the flow part contained needle holes for establishing
328 connection with the media perfusion system.

329 To confirm tissue culture capability, we co-printed cell-laden fugitive inks with
330 simple “one-to-two” channeled tissue as described above, with the hydrogels being
331 printed on a specially-designed flow chamber. A 10% GelMA solution was prepared
332 at 37°C and used as elastic ink to fully encapsulate the printed features in the flow
333 chamber, and this was followed by photopolymerization to cross-link the GelMA.
334 Next, the fugitive inks were liquefied and removed from the 3D construct. The flow
335 chamber connected with inlet and outlet tubes through luer connector perfusion
336 system with pumps. Red pigment was added to the medium for coloration (Figure 4C).
337 We used 1.6-mm-inner-diameter tubes and set the inlet perfusion rate at 2-20 $\mu\text{L min}^{-1}$
338 for stable and perfusable culture. Importantly, over the course of 7 days of perfusion,
339 the channels always maintained an integrity pattern (Figure 4D; Figure S4B and
340 Movie S2, S3, Supporting Information).


341 For developing viable strategies for vascularization in tissue engineering, we
342 must carefully explore cell morphology for ensuring high biocompatibility. While cell
343 aggregate cultures hold tremendous potential due to their organotypic cellular
344 interaction, it is easy to improve their viability and function when compared with
345 single cells.^[42-45] A previous study has reported the capability of fibroblast aggregates
346 to induce vascularization.^[24] We developed aggregates prepared by co-culturing 80%
347 HUVECs and 20% HFFs. It was observed that the HUVECs in the co-culture
348 aggregates assembled to form a vessel-like structure. To fabricate more engineered
349 and vascularized tissues, we used RFP-HUVECs and HFFs co-culture aggregates
350 encapsulated in 3GF inks with gelatin as the fugitive inks. As indicated previously, we

351 initially fabricated the “one-to-two” channeled tissues with HUVECs and MSCs (VOs)
352 shown in Figure 4E. Also, HUVEC and MSC as single cell were encapsulated in 3GF
353 and printed for comparison. To investigate the viability of both single cells and cell
354 aggregates in perfusion culture after 1 days, 4 days and 7 days, we used calcein AM
355 and EthD for staining and confocal imaging, while Image J was used for statistical
356 analysis of data (Figure 4F, G, H; Figure S5, Supporting Information). At day 1, the
357 cell viability was 66% for aggregates. However, the values increased to 71% and 80%
358 at day 4 and day 7, respectively. It was found that printed single cells had no more
359 than 40% viability after 7 days. We found that the initial cell viability was lower
360 compared with that at day 7, suggesting that the printed cells proliferated over time.
361 The observations suggest that our 3D bioprinting approach to printed HUVEC
362 aggregates is less destructive than that observed in single cell.

363 To demonstrate the formation of vascularized tissues, we used HUVECs and
364 HFFs co-culture aggregates. After a 3-day culture of printed cellular aggregate
365 incubation with 3GF hydrogels, morphological assessment for vascularization and
366 lumen formation was performed (Figure 4I, Movie S4, Supporting Information).
367 Additional network vascularization was studied using 3D-reconstructed confocal,
368 whereby the printed tissues showed multiple cellular aggregates forming
369 capillary-like networks. This observation suggests that those aggregates were
370 important for the formation of vascularized networks *in vitro*. Furthermore, to form
371 vasculature channels, we lined HUVECs in the printed channels of VO. After
372 overnight perfusion, HUVECs attached to each vessel (Figure 4J). Moreover, it

373 formed a confluent monolayer after one week of culture incubation. It is important
374 that angiogenic HUVEC-based invasions occurred in the vascular channel, with
375 sprout formation bearing lumen-like structures. Although the morphology of the
376 budded sprouts is in its preliminary stages, the exciting perspective is the formation of
377 connections between sprout tips and the HUVEC aggregates. We have demonstrated
378 using SEM the morphology of HUVECs and MSCs encapsulated in 3GF, whereby the
379 attached HUVECs and HUVEC-based aggregates have been shown after different
380 time periods of incubation (Figure. 4K, L).

381



382

383 **Figure 4.** Tissue perfusion culture and aggregate printing for vascular network

384 formation *in vitro*. A) Schematic diagram of perfusion equipment showing

385 digital-control peristaltic pump, reservoir of culture medium, and perfusion chambers

386 containing printed tissues. B) Perfusion chamber schematic diagram showing flow

387 parts, top and bottom glass, luer connector, needles, screw, and sealing ring. C)

388 Schematic diagram showing flow chamber and PU tube-based connections. D) VOs

389 perfused in one week. Images show channel perfusion on days 2, 4, 5, and 7,

390 respectively. E) Schematic diagram showing HUVEC and MSC co-culture aggregates
391 mixed with GF inks printed as VOs. F) Live/dead fluorescence images showing
392 HUVECs and MSCs co-culture aggregates. Scale bar represents 200 μm . G)
393 Live/dead fluorescence images showing co-printed HUVECs and MSCs. Scale bar
394 represents 200 μm . H) Cell viability assay results of printed HUVECs and MSCs
395 co-printed compared with HUVECs and MSCs co-culture aggregates on days 1, 4 and
396 7 after printing. I) Fluorescence composite images of (i) top view and (ii)
397 cross-section displaying vascularized cells in printed GF inks. Scale bar represents
398 200 μm . J) Fluorescence composite images of (i) top view and (ii) cross-section
399 displaying RFP-HUVECs seeded in printed channels and perivascular cells. Scale bar
400 represents 200 μm . K) SEM images showing HUVECs and MSCs co-cultures in GF
401 inks after printing. (i) Scale bar represents 20 μm . (ii) Scale bar represents 10 μm . L)
402 SEM images showing HUVECs attached in channels. (i) Scale bar represents 20 μm .
403 (ii) Scale bar represents 10 μm . The data are presented as the mean \pm SD. *: $p < 0.1$, **: $p < 0.01$, ***: $p < 0.001$.

405

406 **2.4 Fabricating vascularized liver tissues as *in vitro* model and its implantation *in*** 407 ***vivo***

408 Previously, it has been shown that a vascularized tissue environment is preferred due
409 to its better cell-cell interactions, and improved hepatocytic function. In this study, in
410 order to fabricate liver models *in vitro*, we encapsulated HAs by replacing
411 HUVEC-based aggregates within the cell-laden hydrogel. HepG2 is a cancer cell line,

412 which has been used as a model cell for tissue regeneration *in vitro* for studying
413 hepatic function.^[46-48] For HepG2 aggregate formation, 60% HepG2, 30% HUVECs,
414 and 10% HFFs were mixed, and this was based on the percentages of the different cell
415 types as observed *in vivo*. To confirm the distribution of the three cell types
416 throughout the aggregate, their 3D distribution was assessed using confocal
417 fluorescence microscopy (**Figure 5B**). Notably, after 2 days of incubation, the
418 aggregates' diameters were about 200 μm and showed albumin (ALB) expression
419 (Figure 5B). Importantly, we printed multi-HAs as shown in Figure 5C, the ALB
420 expression increased after 7 days of perfusion culture *in vitro*. This difference was
421 possibly due to better nutrition and oxygen support in the tissue.

422 It is observed that HUVECs in multi-HAs do not form connections with each
423 other. Thus, we encapsulated HUVECs, MSCs, and HAs into the matrix hydrogel to
424 generate more vascularization in the tissue. Here, the HUVECs and MSCs were
425 mixed in appropriate ratios. HUVECs and MSCs were seeded at 1×10^7 cells mL^{-1} and
426 1×10^6 cells mL^{-1} , respectively. Judging from the 3D-reconstructed confocal images,
427 the printed tissues showed formation of capillary-like networks by HUVECs and
428 MSCs along with formation of multiple cell-aggregates (Figure 5D, Movie S5,
429 Supporting Information). This suggests that HUVECs and MSCs single cells, as well
430 as HAs are important for the formation of vascularized liver tissues *in vitro*. To
431 evaluate the liver function of this tissue, we assessed the expression of hepatic
432 specific genes by quantitative PCR (qPCR) analysis at different periods of culture
433 (Figure S6). It is notable that ALB and hepatocyte nuclear factor 4 alpha (*HNF4A*)


434 expression levels were increased and reached peak values after 2 weeks of culturing,
435 and the human alpha 1-antitrypsin (AAT) expression was at its highest level at day 4.
436 However, *ASGPR1* and *CK18* expression levels decreased, while the liver tissue
437 *CK18* expression level was lower than that in two-dimensional (2D) culture of HepG2
438 cells. Compared with 2D HepG2 culture, only HepG2 (Hs) and HAs are printed in the
439 tissue, while the HO expressed the highest levels of *ALB*, *ASGPR1*, *PROX1*, *AAT*,
440 *CEBPA* and *CD31* (Figure 5A). Liver function-related protein expression of ALB
441 between different culture periods was assessed using ELISA (Figure 5E). ALB
442 secretion was the highest after culturing for 6 days, gradually declining thereafter.
443 Thus, liver tissue cultured for 7 days was chosen for further experiments.

444 To analyze the functionality of vascularized liver tissues *in vivo*, we implanted
445 HOs subperitoneally in mice. We chose 3GF hydrogel as the control. To avoid
446 immunological rejection, after liver tissue transplantation, we injected cyclosporine
447 into the abdominal cavities of the mice. The blood vascular system is a critical system
448 for nutrients and oxygen supply. The liver tissue transplants showed
449 neovascularization at day 7 after transplantation (Figure 5F). However, this
450 phenomenon could not be observed in the 3GF hydrogel treated test group.

451 To demonstrate that these tissues can be used for direct surgical anastomosis to
452 host vasculature, we leveraged this “one-to-two” channeled tissues combining 5%
453 GelMA as inner elastic inks and external elastic inks outside fugitive inks and
454 cell-laden inks respectively, encapsulated in poly(dimethylsiloxane) (PDMS) were
455 connected to the arteria vessel of adult SD rats, in artery-to-vein mode. The tissues

456 were connected using PU tubes after PDMS-based encapsulation (Figure 5G, Movie
457 S6, Supporting Information). These inlet, outlet PU tubes were connected to the
458 carotid artery and jugular vein, respectively (Figure 5H, Movie S7, Supporting
459 Information). The PU tubes have been shown to be antithrombotic in *in vivo* vascular
460 grafts. To prevent blood clotting in the PU tubes, the animals were injected with
461 heparin during surgery, as well as within 4 days after the surgery. After the
462 vasculature connection being established, the arterial clip was removed to allow blood
463 perfusion. Although this mode was technically challenging owing to the high pressure,
464 the “one-to-two” channel in the hepatic tissue was maintained. One week after the
465 implantation, thrombus was observed and the tissue was removed.

466



467

468 **Figure 5.** *In vitro* and *in vivo* fabrication of vascular liver. A) Quantitative PCR
 469 analysis of the hepatic markers (*ALB*, *HNF1A*, *ASGPR1*, *PROX1*, *HNF4A*, *HNF6*,
 470 *AAT*, *CEBPA*, *CK18*), and the vascular marker (*CD31*). B) Fluorescence images of the
 471 HAs and multi-HAs showing ALB expression. Scale bar represents 100 μ m. C)
 472 Fluorescence images of multi-HAs showing ALB expression. Scale bar represents 50
 473 μ m. D) Fluorescence images of HOs displaying HAs formed by GFP-HepG2,
 474 RFP-HUVECs, and RFP-HUVECs vascularization. Scale bar represents 200 μ m. E)
 475 ALB expression in cell culture supernatants of HOs as measured by ELISA. F)

476 Observation of transplanted tissues under the subperitoneal zone showing
477 neovascularization of the liver tissue transplants. Scale bar represents 1 cm. G)
478 Images showing “one-to-two” channeled tissues encapsulated in PDMS connected
479 with PU tubes. Scale bar represents 1 cm. H) Observation of transplanted tissues after
480 establishment of connections with carotid artery and jugular vein showing arterial clip
481 slip and establishment of blood perfusion. Scale bar represents 1 cm. The data are
482 presented as the mean \pm SD. *: $p < 0.1$, **: $p < 0.01$, ***: $p < 0.001$.

483 In this study, we present a facile multi-materials bioprinting strategy for
484 constructing centimeter-scale liver-like tissues with branched perfusable vascular
485 networks using a model cell-laden hydrogel formed with organoids bearing bioink.
486 The cell aggregates were deposited in the cell-laden matrix to modulate
487 morphogenesis in space and time. Besides the bioprinted vasculatures, 3D capillary
488 networks were formed successfully using vascularized HUVECs, which supported the
489 nutrient and oxygen requirement of the centimeter-scale liver. We also characterized
490 the HepG2 cells in the tissue, which displayed increased liver-specific gene
491 expression, and determined liver functions, such as albumin secretion, 7 days after
492 differentiation in both *in vitro* and *in vivo* systems. Soft cell-laden elastic hydrogel
493 was tested *in vivo* by direct surgical anastomosis, which has been rarely reported
494 earlier. This work provides a viable and rapid design strategy for biofabrication of
495 engineered tissues, as well as *in vivo* testing using surgical anastomosis for
496 establishing an active vascular network for optimal transport of blood and tissue
497 function.

498 The printability and biocompatibility of bioink largely affect the construction of
499 soft tissues with vascular network.^[49] High concentrations of polymer to some extent
500 can strengthen the hydrogel viscosity.^[50] High viscosity allows extruded bioink to
501 better hold its shape and improves mechanical stability, which is especially beneficial
502 in printing larger structures with good resolution.^[51] However, higher viscosity
503 increases shear stress during printing, which can damage cells by directly disrupting
504 cell membranes, thereby reducing the rate of proliferation in the surviving cells.
505 Furthermore, it is necessary to use low-concentration (i.e. <5%) GelMA for
506 bioprinting, which can not only achieve higher cell viability after printing, but also
507 facilitate cell proliferation and migration within the printed structure.^[32] In the
508 printing process of low-concentration GelMA, problems may occur, including low
509 printing resolution, poor shape fidelity, even nonuniform cell distribution and cell
510 deposition. It's been a heated research topic on the bioprinting of low-concentration
511 (i.e. <5%) GelMA. Current approaches adapted to tackle the challenge mainly include
512 the additives of other materials and printing hydrogels under low temperature.^[32, 52]
513 Technically speaking, adding other materials is not categorized in the field of
514 low-concentration bioprinting. What's more, bioprinting hydrogel under low
515 temperature may be problematic including poor shape fidelity and decreased cell
516 viability (nearly 90%). Therefore, low-concentration GelMA could achieve fine
517 bioprinting with enhancing high cell viability, which is a significant research problem
518 to be resolved. In this study, we used 3% GelMA as cell-laden inks with the secondary
519 temperature of the BiopHead, which promote high cell viability and printing accuracy.

520 The vasculature is responsible for mass transport which sustains the metabolic
521 requirements of engineered tissues. Dynamic culture under continuous perfusion
522 could supply nutrients and oxygen, while removing metabolic wastes through stable
523 inter-connected vascular networks.^[53-54] In continuous perfusion culture such as cell
524 aggregates and organoids, higher cell densities can be sustained.^[20] Furthermore, this
525 versatile platform also can be used to precisely control the growth and differentiation
526 of cultured tissue.^[17] With addition of appropriate growth factors and culture medium,
527 perfusion tissue can be stimulated to attain maturity and achieve efficient
528 functionalization.^[55]

529

530 **3. Conclusions**

531 Three-dimensional printing holds great promise for engineering whole organs,
532 but the field is still in its nascent stage with many unresolved challenges. In this study,
533 we demonstrate the use of low concentrations of GelMA with fibrin for the first time,
534 as a bioink for extrusion-based printing of vascularized tissues, producing model
535 organ tissues with high-resolution and high cell viability. This 3D engineering-based
536 methodology has allowed us to fabricate vascular networks in centimeter-scale tissues
537 with active tissue functionality. Furthermore, it opens a new avenue for fundamental
538 drug screening studies.

539

540 **4. Experimental Section**

541 *GelMA synthesis:* We used a simple method to synthesize GelMA. First, gelatin (Type
542 A, 300 bloom from porcine skin, Sigma Aldrich) was dissolved in Dulbecco's
543 phosphate-buffered saline (DPBS, Gibco) to make a 10% (w/v) solution, and stirred at
544 60°C for 2 h. Then the temperature was lowered to 50°C, and 0.5 ml methacrylic
545 anhydride (Sigma Aldrich) was slowly added to the gelatin solution with continuous
546 stirring at a rate of 1 mL min⁻¹ per gram of gelatin, to obtain 70% modified GelMA.
547 After 3 hours of reaction, the temperature was reduced to 40°C, and the reaction
548 solution was dialyzed with deionized water. The molecular weight cut-off of the
549 dialysis bag was 14 kDa (Spectrum Labs, Inc.). In order to remove excess methacrylic
550 acid and salts, dialysis was performed at 40°C, and the fluid was changed once a day
551 for a week. The reaction solution was aliquoted, lyophilized, and stored at -80°C. The
552 lyophilized powder was stored at -20°C. Pre-heated sterile DPBS at 60°C was used to
553 dissolve 10% GelMA, and 1 M NaOH was used to adjust the pH to 7.2-7.4. The
554 methacrylation degree of free amine group in GelMA sample was determined by ¹H
555 NMR as previously described.^[56] Before use, 0.1% (w/v) lithium phenyl-2, 4,
556 6-trimethylbenzoylphosphinate (LAP, Sigma Aldrich) was added.

557 *Bioink preparation:* We prepared several types of inks for 3D printing. Cell-laden inks
558 were prepared using GelMA and fibrin (Sigma Aldrich, MO, USA) at different
559 mixing ratios. Fibrinogen was stored at concentration of 25 mg mL⁻¹ in sterile DPBS
560 without calcium and magnesium, and kept at 37°C for 30 min to allow full dissolution.

561 Photocrosslinking was achieved by exposing the GelMA or GelMA-Fibrin
562 prepolymer to 10 mW cm^{-2} UV light (365 nm, Goodun) for 2 min.

563 The 10% gelatin-based bioink was used as the sacrificial material, which was
564 dissolved in pre-heated sterile DPBS at 60°C , and the pH was adjusted to 7.2-7.4 with
565 1 M NaOH. A 10% GelMA solution was used as the elastic material for the *in vitro*
566 perfusion culture. The elastic material used for jugular artery and vein transplantation
567 was poly(dimethylsiloxane) (PDMS, SylgardTM 184 silicone elastomer kit, Dow
568 chemical company). This ink is composed of two elastomers in a weight ratio of 10:1,
569 which were mixed for 30 s at 2000 rpm with a stirring mixer (AE-310, Thinky
570 Corporation) to make the final solution uniform.

571 *Viscosity test:* A viscometer (RST-CPS cone plate rheometer, Brookfield) was used to
572 measure the viscosity of 1%, 2%, 3%, 4%, 5% GelMA, and 3% GelMA+0.25%
573 Fibrin bioink, respectively. First, the temperature of the viscometer measuring plate
574 with a upper plate diameter of 25 mm was cooled to 2°C . The GelMA solution was
575 dropped on the measuring plate, and the distance between the plates was adjusted to
576 $50 \mu\text{m}$. The excess material was wiped off and allowed to stand for 1 min. The upper
577 measuring plate (rotor) was gently rotated before measurement to avoid adhesion
578 between the plates, and the viscosity was measured at a shear rate of 10 s^{-1} with
579 temperature increase of 1°C per min.

580 *Morphology and porosity analysis by Scanning Electron Microscopy (SEM):* The
581 GelMA hydrogel and GelMA-Fibrin hydrogel were immersed in PBS for 24 h at 37°C .
582 For studies of internal porosity, samples were fixed with 3.7% paraformaldehyde

583 (PFA, Fluka) for 30 min, immersed in liquid nitrogen for 60 seconds, freeze-fractured
584 using a cold razor blade, and sublimation at -75°C for 45min, and then sputter coated
585 with Au. All samples were observed by HITACHI S-3000N&Quorum PP3000T
586 Scanning Electron Microscope.

587 *SEM images for hydrogel with cells:* the hydrogel samples with cells were soaked
588 with 2.5% glutaraldehyde at 4°C for 24 h. Then all samples were washed with PBS for
589 3 times, and dehydrated samples through graded ethanol solutions with 15, 30, 50, 70,
590 80, 90, 100, 100% (v/v, in water) for 10 min each time. After that all samples were
591 dried by a critical point drying (CPD) technique using a Bal-Tec 030 instrument.
592 Finally, all samples were coated with Au by a sputter and examined with SEM
593 (phenom pro).

594 *Cell culture and maintenance:* Primary human umbilical vein endothelial cells
595 (HUVECs) and red fluorescent protein-expressing HUVECs (RFP-HUVECs) were
596 maintained in EMG-2 medium (complete EGM-2 BulletKitTM, Lonza). We obtained
597 human umbilical cords from Xinhua Hospital Affiliated to Shanghai Jiaotong
598 University School of Medicine. The collection and use of the obtained umbilical cords
599 were approved by the institutional ethical committee (approval number:
600 XHEC-C-2020-092-1), and informed consent was obtained from all participants.

601 HepG2, human foreskin fibroblast (HFFs), and human umbilical cord MSCs were
602 donated by the National Stem Cell Resource Center, Beijing. HepG2, GFP-HepG2
603 and HFFs were cultured in Dulbecco's modified Eagle medium containing high
604 glucose and sodium pyruvate (DMEM, Gibco) supplemented with 10% fetal bovine

605 serum (FBS, Bioind), 1% penicillin/streptomycin (Gibco). MSCs and GFP-MSCs
606 were cultured in Dulbecco's modified Eagle medium containing high glucose and
607 sodium pyruvate (DMEM, Gibco) supplemented with 15% fetal bovine serum (FBS,
608 Bioind), 1% non-essential amino acid solution (NEAA, Gibco), 1% GlutaMAX™
609 (Gibco), 1% penicillin/streptomycin (Gibco). All cells were cultured at 37°C and 5%
610 CO₂ in an incubator, and the medium was changed every 2 days. HUVECs,
611 RFP-HUVECs and HFFs were not used beyond the 10th passage.

612 For HUVEC cell aggregate preparation, 8×10⁴ HUVECs and 2×10⁴ HFFs were
613 suspended in 1.5 mL medium and seeded into each well of a 24-well Kuraray
614 ultra-low attachment plate (round-bottom type, Elplasia). Each plate has 400
615 microwells. Cells supplemented with EGM-2 were seeded evenly in the microwells,
616 which were then allowed to self-aggregate over a time of 24 h. For HepG2 aggregate
617 preparation, 6×10⁴ HepG2, 3×10⁴ HUVECs, and 1×10⁴ HFFs were suspended in 1.5
618 mL medium and seeded in a well. Cells were maintained in EGM-2, and the medium
619 was changed 2-3 times every day by replacing 1 mL of the supernatant in each well.

620 *Encapsulation of HUVECs and MSCs in hydrogels:* When cells cultured reached 90%
621 confluency, the culture medium was discarded and cells were washed with PBS, and
622 then incubated with 0.25% Trypsin-EDTA (Gibco) for 1 min at 37°C to detach the
623 cells from the culture dishes. The cell suspension was centrifuged at 1200 rpm for 3
624 min at room temperature. The supernatant was discarded, and the cells were
625 resuspended in hydrogels at 37 °C. For RFP-HUVECs and GFP-MSCs
626 co-encapsulation, we mixed 1×10⁶ RFP-HUVECs and 1×10⁶ GFP-MSCs with 3%

627 GelMA, 3% GelMA+0.25% fibrin, 3% GelMA+1% fibrin, 5% GelMA, 5%
628 GelMA+0.25% fibrin, respectively. A volume of 20 μ L of the cell-prepolymer mixture
629 was dispensed in each well of a 24-well flat bottom cell culture plate.
630 Photocrosslinking was achieved by exposing the mixture to 10 mW cm⁻² UV light
631 (365nm, Goodun) for 2 min. The encapsulated hydrogels were then cultured with
632 EGM-2 medium.

633 *Bioprinting platform and hardware:* A 3D bioprinter developed by the Shenyang
634 Institute of Automation, Chinese Academy of Sciences, was used for the 3D vascular
635 tissue printing experiment. The main components of the printer include 5 print heads,
636 a print platform, and a print bin, which will allow multi-materials printing. As the core
637 component of the printer, the print head included an integrated electrical interface, a
638 two-stage temperature control unit, a two-stage temperature sensor, a water-cooling
639 block, and two printing components (electric extrusion and pneumatic extrusion). The
640 printing platform can be set at a wide range of temperatures ranging from -10°C to
641 60°C. The printed 3D vascular network tissue was cured using a low-temperature gel.
642 The printing chamber has an ultraviolet sterilization function which allows aseptic
643 printing.

644 *Fabrication process:* The 3D drawing software SolidWorks 2018 (SolidWorks
645 Software, Inc., La Jolla, USA) was used to model the designed vascular tissue, import
646 the geometric model into the self-developed software Bipcoder to configure printing
647 parameters, and generate the G code. For *in vitro* perfusion culturing, 10% gelatin, 3%
648 GelMA+0.25% fibrin were used as the sacrificial material and the cell-laden material

649 respectively. The feeder needles transfer those inks into the two print heads, and allow
650 maintenance of the temperature of the printing silo and the printing needle,
651 respectively. The temperature of the printing silo was set slightly higher (8°C) than
652 the gel point temperature (6°C), and the temperature of the printing needle was based
653 on the temperature representing the gel point in the printability map. For
654 transplantation printing, 10% gelatin, 3% GelMA+0.25% fibrin, and 5% GelMA were
655 used as the sacrificial material, cell-laden material, and elastic material, respectively,
656 and loaded into respective print heads. All needles used for printing have a diameter
657 of 200 μm. Photocrosslinking was achieved using UV light (365nm, Goodun) at the
658 wavelength of 365 nm for 2 min after printing was completed. Then it is placed in
659 thrombin solution (5 U mL⁻¹) at 37°C to dissolve and remove the internal gelatin
660 material and allow formation of a vascular channel structure.

661 *Endothelial monolayer and vascular network formation:* The printed structure was
662 mounted in a customized chamber. We used 10% GelMA to encapsulate the printed
663 constructs for perfusion. The cells were resuspended to have 1 × 10⁷ cells mL⁻¹ in
664 EGM-2 medium. To form an endothelial monolayer, 10 μL cell resuspension was
665 seeded into the channel using a micropipette. Adhesion of the cells to the bottom
666 surface was allowed for 30 min, followed by flipping of the system and incubation for
667 30 min to allow adherence to the top surface. After the seeding period, the constructs
668 were put into the perfusion incubator (TEB500, Ebers) with the tubing inset into the
669 flow chamber. Unattached cells were washed away with culture medium EGM-2 and

670 5 ng mL⁻¹ VEGF (R&D). Perfusion rate was set to 2-20 μ L min⁻¹. The constructs were
671 cultured for several days before further characterizations.

672 *Cell viability assay:* Cell viability was analyzed using LIVE/DEAD
673 Viability/Cytotoxicity Kit (Life Technologies). After washing the cells three times
674 with phosphate-buffered saline (PBS), a PBS solution containing 0.5 μ L mL⁻¹ calcein
675 AM and 2 μ L mL⁻¹ EthD was used to stain the cells for 20 min in the dark. The cells
676 were then washed three times with PBS to remove residual reagents. An inverted
677 confocal microscope was used to take the fluorescence images (Calcein AM: Ex 488
678 nm, Em 505-525 nm; EthD: Ex 559 nm, Em 600-630 nm).

679 *SD mice and HOs transplantation:* All animal experiments were approved by the
680 Institutional Animal Care and Use Committee (IACUC) of the Institute of Zoology,
681 Chinese Academy of Sciences in accordance with institutional and national guidelines
682 (Ethical approval No. IOZ20180063). To analyze the functionality of vascularized
683 liver tissues in vivo, we implanted HOs it into subperitoneal of mice after
684 anaesthetising.

685 *Immunofluorescence staining:* For ALB staining, printed tissues were fixed with 4%
686 paraformaldehyde for 30 min at room temperature, and permeabilized with 0.5%
687 Triton X-100 (Sigma) for 30 min, followed by PBS washing (3 times). The tissues
688 were blocked with 3% bovine serum albumin (BSA) in PBS overnight. Then they
689 were incubated for 2 days with a primary antibody anti-ALB (R&D, MAB1455-SP,
690 1:100) in blocking buffer at 4 °C, followed by PBS washing (3 times). The tissues
691 were then incubated with fluorescence-conjugated secondary antibodies Alexa Fluor

692 488 (Donkey anti-mouse, Invitrogen, A21202, 1:500) diluted in PBS for 2 days in the
693 dark at 4°C. Finally, the nuclei were stained with Hoechst 33342 (Invitrogen, 1:1000)
694 for 10 min, followed by three PBS washes.

695 *Real-time quantitative polymerase chain reaction:* Total RNA was extracted from
696 printed tissues and cells using TRIzol (Invitrogen), following the manufacturer's
697 instructions. One microgram of RNA was reverse transcribed into cDNA using a
698 PrimeScript™ RT reagent Kit (TaKaRa, RR037A) in a 20 µl reaction. Real-time
699 quantitative PCR (qPCR) was performed and analyzed using a CFX96™ real-time
700 system (Bio-Rad) with TB Green Premix Ex Taq™ (TaKaRa, RR420A). The
701 expression level of *GAPDH* was used for internal normalization. The details of the
702 primers for HepG2 and HUVECs have been listed in Supplementary Table 1.

703 *Albumin ELISAs:* To measure ALB secretion, the 3D printed tissues were cultured for
704 various time periods. Culture supernatants were collected at 24 h after a medium
705 change and stored at -80°C before analysis. ELISAs were performed using a human
706 albumin ELISA kit (Abcam, ab179887) according to the manufacturer's instructions.

707 *Imaging and analysis:* Photographs of fabricated tissues were acquired using Leica
708 SAPO stereo microscopes and high-speed CMOS cameras (PCO. dimax HS, PCO).
709 Confocal microscopy was performed using a Leica Dmil fluorescent microscope and
710 a Zeiss LSM 780 fluorescent microscope. Three-dimensional projections were
711 generated in Imaris (Imaris 9.0.2, Bitplane Scientific Software) and ZEN software
712 (Zeiss). For cell counting and length calculation, a semi-automated process in Image J
713 was used.

714 *Statistics*: Data are presented as mean \pm SD (n=3). The t-test was performed to
715 determine significant differences using GraphPad Prism 8 (GraphPad Software, Inc.,
716 La Jolla, USA). The significance levels (p-values) are indicated with asterisks and
717 specific p-values are provided in each figure legend.

718 **Supporting Information**

719 Supporting Information is available from the Wiley Online Library or from the
720 author.

721 **Acknowledgements**

722 Xin Liu, Xinhuan Wang, Lulu Sun, and Liming Zhang contributed equally to this
723 work. The authors acknowledge funding support from the Strategic Priority Research
724 Program of Chinese Academy of Sciences, Grant No. XDA16020802, XDA16020803
725 and XDA16020804, National Key Research and Development Program of China
726 2018YFE0204403, CAS Pioneer Hundred Talents Program, Y829F11102, the
727 National Key Research and Development Project under Grant 2020YFB1313100, the
728 National Natural Science Foundation of China (51875557), the Research Equipment
729 Development Program of the Chinese Academy of Sciences (YJKYYQ20170042,
730 YJKYYQ20190045), Foundation of State Key Laboratory of Robotics (2017-Z16),
731 the China Postdoctoral Science Foundation (2020M670454), and Financial supports
732 from the State Key Laboratory of Membrane and the State Key Laboratory of
733 Robotics are also gratefully acknowledged. We thank Mr. Kai Li for technical support
734 of graphical design and Dr. Ji for grammar revision.

735 **Author Contributions**

736 X. Liu developed the multi-scale vascular tissues, designed and performed
737 experiments, analyzed data and prepared manuscript. Dr. X. Wang contributed to
738 GelMA synthesis, polymer characterization, SEM analysis, endothelization and
739 vascular network formation, subperitoneally transplantation and carotid artery and
740 jugular vein connection. L. Zhang performed viscosity test, bioprinting parameter
741 testing, fabrication process. Dr. L. Sun performed HUVECs and MSCs encapsulation
742 experiments, HUVEC cell aggregate preparation. Dr. H. Wang performed bioprinting
743 platform and hardware designed. Dr. H. Zhao performed GelMA synthesis. Z. Zhang
744 performed the HUVECs isolation. Dr. Y. Huang performed polymer characterization.
745 J. Zhang and B. Song performed perfusion experiments. C. Li performed HUVECs
746 and MSCs encapsulation experiments. H. Zhang and S. Li performed bioprinting
747 parameter testing, fabrication process.

748 **Conflict of Interest**

749 The authors declare no conflict of interest.

750 **Date Availability Statement**

751 The data that support the findings of this study are available from the corresponding
752 author upon reasonable request.

753 **Keywords**

754 3D bioprinting, vasculature, vascularization, perfusion, transplantation.

755 Received: ((will be filled in by the editorial staff))

756 Revised: ((will be filled in by the editorial staff))

757

Published online: ((will be filled in by the editorial staff))

758

759 **References**

- 760 [1] S. V. Murphy, A. Atala, *Nat. Biotechnol.* **2014**, 32, 773.
- 761 [2] Y. S. Zhang, K. Yue, J. Aleman, K. M. Moghaddam, S. M. Bakht, J. Yang, W.
762 Jia, V. Dell'Erba, P. Assawes, S. R. Shin, M. R. Dokmeci, R. Oklu, A.
763 Khademhosseini, *Ann. Biomed. Eng.* **2017**, 45, 148.
- 764 [3] L. Moroni, T. Boland, J. A. Burdick, C. De Maria, B. Derby, G. Forgacs, J.
765 Groll, Q. Li, J. Malda, V. A. Mironov, C. Mota, M. Nakamura, W. Shu, S.
766 Takeuchi, T. B. F. Woodfield, T. Xu, J. J. Yoo, G. Vozzi, *Trends Biotechnol.*
767 **2018**, 36, 384.
- 768 [4] T. Gao, G. J. Gillispie, J. S. Copus, A. K. Pr, Y. J. Seol, A. Atala, J. J. Yoo, S. J.
769 Lee, *Biofabrication* **2018**, 10, 034106.
- 770 [5] P. S. Gungor-Ozkerim, I. Inci, Y. S. Zhang, A. Khademhosseini, M. R.
771 Dokmeci, *Biomater. Sci.* **2018**, 6, 915.
- 772 [6] Y. S. Zhang, A. Khademhosseini, *Science* **2017**, 356, eaaf3627.
- 773 [7] N. F. Huang, V. Serpooshan, V. B. Morris, N. Sayed, G. Pardon, O. J. Abilez,
774 K. H. Nakayama, B. L. Pruitt, S. M. Wu, Y. S. Yoon, J. Zhang, J. C. Wu,
775 *Commun. Biol.* **2018**, 1, 199.
- 776 [8] S. Maharjan, J. Alva, C. Cámara, A. G. Rubio, D. Hernández, C. Delavaux, E.
777 Correa, M. D. Romo, D. Bonilla, M. L. Santiago, W. Li, F. Cheng, G. Ying, Y.
778 S. Zhang, *Matter* **2021**, 4, 217.
- 779 [9] D. Richards, J. Jia, M. Yost, R. Markwald, Y. Mei, *Ann. Biomed. Eng.* **2017**,
780 45, 132.
- 781 [10] C. K. Griffith, C. Miller, R. C. A. Sainson, J. W. Calvert, N. L. Jeon, C. C. W.
782 Hughes, S. C. George, *Tissue Engineering* **2005**, 11, 257.
- 783 [11] Y. S. Zhang, A. Khademhosseini, in *Tissue-Engineered Vascular Grafts*, DOI:
784 10.1007/978-3-030-05336-9_11 **2020**, Ch. Chapter 11, p. 321.
- 785 [12] X. Cao, S. Maharjan, R. Ashfaq, J. Shin, Y. Shrike Zhang, *Engineering* **2020**,
786 DOI: <https://doi.org/10.1016/j.eng.2020.03.019>.
- 787 [13] P. Datta, B. Ayan, I. T. Ozbolat, *Acta Biomater.* **2017**, 51, 1.
- 788 [14] I. T. Ozbolat, M. Hospodiuk, *Biomaterials* **2016**, 76, 321.
- 789 [15] H. Gudapati, M. Dey, I. Ozbolat, *Biomaterials* **2016**, 102, 20.
- 790 [16] J. S. Miller, K. R. Stevens, M. T. Yang, B. M. Baker, D.-H. T. Nguyen, D. M.

- 791 Cohen, E. Toro, A. A. Chen, P. A. Galie, X. Yu, R. Chaturvedi, S. N. Bhatia, C.
792 S. Chen, *Nat. Mater.* **2012**, 11, 768.
- 793 [17] D. B. Kolesky, K. A. Homan, M. A. Skylar-Scott, J. A. Lewis, *Proc. Natl.*
794 *Acad. Sci. USA* **2016**, 113, 3179.
- 795 [18] L. E. Bertassoni, M. Cecconi, V. Manoharan, M. Nikkhah, J. Hjortnaes, A. L.
796 Cristino, G. Barabaschi, D. Demarchi, M. R. Dokmeci, Y. Yang, A.
797 Khademhosseini, *Lab on a Chip* **2014**, 14, 2202.
- 798 [19] L. Zhao, V. K. Lee, S.-S. Yoo, G. Dai, X. Intes, *Biomaterials* **2012**, 33, 5325.
- 799 [20] M. A. Skylar-Scott, S. G. Uzel, L. L. Nam, J. H. Ahrens, R. L. Truby, S.
800 Damaraju, J. A. Lewis, *Sci. adv.* **2019**, 5, eaaw2459.
- 801 [21] B. Trappmann, B. M. Baker, W. J. Polacheck, C. K. Choi, J. A. Burdick, C. S.
802 Chen, *Nat. Commun.* **2017**, 8, 371.
- 803 [22] T. J. Hinton, Q. Jallerat, R. N. Palchesko, J. H. Park, M. S. Grodzicki, H.-J.
804 Shue, M. H. Ramadan, A. R. Hudson, A. W. Feinberg, *Sci. Adv.* **2015**, 1,
805 e1500758.
- 806 [23] H.-H. G. Song, K. M. Park, S. Gerecht, *Adv. Drug Deliv. Rev.* **2014**, 79-80, 19.
- 807 [24] Y. Nashimoto, T. Hayashi, I. Kunita, A. Nakamasu, Y.-s. Torisawa, M.
808 Nakayama, H. Takigawa-Imamura, H. Kotera, K. Nishiyama, T. Miura, R.
809 Yokokawa, *Integrative Biology* **2017**, 9, 506.
- 810 [25] I. T. Ozbolat, *Trends Biotechnol.* **2015**, 33, 395.
- 811 [26] J. D. Baranski, R. R. Chaturvedi, K. R. Stevens, J. Eyckmans, B. Carvalho, R.
812 D. Solorzano, M. T. Yang, J. S. Miller, S. N. Bhatia, C. S. Chen, *Proc. Natl.*
813 *Acad. Sci. USA* **2013**, 110, 7586.
- 814 [27] X. Ye, L. Lu, M. E. Kolewe, H. Park, B. L. Larson, E. S. Kim, L. E. Freed,
815 *Biomaterials* **2013**, 34, 10007.
- 816 [28] B. Zhang, M. Montgomery, M. D. Chamberlain, S. Ogawa, A. Korolj, A.
817 Pahnke, L. A. Wells, S. Masse, J. Kim, L. Reis, A. Momen, S. S. Nunes, A. R.
818 Wheeler, K. Nanthakumar, G. Keller, M. V. Sefton, M. Radisic, *Nat. Mater.*
819 **2016**, 15, 669.
- 820 [29] I. S. Kinstlinger, S. H. Saxton, G. A. Calderon, K. V. Ruiz, D. R. Yalacki, P. R.
821 Deme, J. E. Rosenkrantz, J. D. Louis-Rosenberg, F. Johansson, K. D. Janson,
822 D. W. Sazer, S. S. Panchavati, K.-D. Bissig, K. R. Stevens, J. S. Miller, *Nat.*

- 823 *Biomed. Eng.* **2020**, 4, 916.
- 824 [30] C. Colosi, S. R. Shin, V. Manoharan, S. Massa, M. Costantini, A. Barbetta, M.
825 R. Dokmeci, M. Dentini, A. Khademhosseini, *Adv. Mater.* **2016**, 28, 677.
- 826 [31] J. Yin, M. Yan, Y. Wang, J. Fu, H. Suo, *ACS Appl. Mater. Interfaces* **2018**, 10,
827 6849.
- 828 [32] W. Liu, M. A. Heinrich, Y. Zhou, A. Akpek, N. Hu, X. Liu, X. Guan, Z. Zhong,
829 X. Jin, A. Khademhosseini, Y. S. Zhang, *Adv. Healthc. Mater.* **2017**, 6.
- 830 [33] A. I. Van Den Bulcke, B. Bogdanov, N. De Rooze, E. H. Schacht, M.
831 Cornelissen, H. Berghmans, *Biomacromolecules* **2000**, 1, 31.
- 832 [34] J. W. Nichol, S. T. Koshy, H. Bae, C. M. Hwang, S. Yamanlar, A.
833 Khademhosseini, *Biomaterials* **2010**, 31, 5536.
- 834 [35] M. Nikkhah, N. Eshak, P. Zorlutuna, N. Annabi, M. Castello, K. Kim, A.
835 Dolatshahi-Pirouz, F. Edalat, H. Bae, Y. Yang, A. Khademhosseini,
836 *Biomaterials* **2012**, 33, 9009.
- 837 [36] Y.-C. Chen, R.-Z. Lin, H. Qi, Y. Yang, H. Bae, J. M. Melero-Martin, A.
838 Khademhosseini, *Adv. Funct. Mater.* **2012**, 22, 2027.
- 839 [37] D. B. Kolesky, R. L. Truby, A. S. Gladman, T. A. Busbee, K. A. Homan, J. A.
840 Lewis, *Adv. Mater.* **2014**, 26, 3124.
- 841 [38] W. Jia, P. S. Gungor-Ozkerim, Y. S. Zhang, K. Yue, K. Zhu, W. Liu, Q. Pi, B.
842 Byambaa, M. R. Dokmeci, S. R. Shin, A. Khademhosseini, *Biomaterials* **2016**,
843 106, 58.
- 844 [39] R. R. Rao, A. W. Peterson, J. Ceccarelli, A. J. Putnam, J. P. Stegemann,
845 *Angiogenesis* **2012**, 15, 253.
- 846 [40] G. A. Calderon, P. Thai, C. W. Hsu, B. Grigoryan, S. M. Gibson, M. E.
847 Dickinson, J. S. Miller, *Biomater. Sci.* **2017**, 5, 1652.
- 848 [41] A. P. Dhand, J. H. Galarraga, J. A. Burdick, *Trends Biotechnol.* **2020**, DOI:
849 <https://doi.org/10.1016/j.tibtech.2020.08.007>.
- 850 [42] A. C. Daly, M. D. Davidson, J. A. Burdick, *Nat. Commun.* **2021**, 12, 753.
- 851 [43] D. J. Richards, Y. Li, C. M. Kerr, J. Yao, G. C. Beeson, R. C. Coyle, X. Chen,
852 J. Jia, B. Damon, R. Wilson, E. Starr Hazard, G. Hardiman, D. R. Menick, C.
853 C. Beeson, H. Yao, T. Ye, Y. Mei, *Nat. Biomed. Eng.* **2020**, 4, 446.
- 854 [44] M.-O. Lee, K. B. Jung, S.-J. Jo, S.-A. Hyun, K.-S. Moon, J.-W. Seo, S.-H.

- 855 Kim, M.-Y. Son, *Journal of Biological Engineering* **2019**, 13, 15.
- 856 [45] Q. Tan, K. M. Choi, D. Sicard, D. J. Tschumperlin, *Biomaterials* **2017**, 113,
857 118.
- 858 [46] H. Jeon, K. Kang, S. A. Park, W. D. Kim, S. S. Paik, S.-H. Lee, J. Jeong, D.
859 Choi, *Gut Liver* **2017**, 11, 121.
- 860 [47] T. Billiet, E. Gevaert, T. De Schryver, M. Cornelissen, P. Dubruel,
861 *Biomaterials* **2014**, 35, 49.
- 862 [48] C.-A. E. Suurmond, S. Lasli, F. W. van den Dolder, A. Ung, H.-J. Kim, P.
863 Bandaru, K. Lee, H.-J. Cho, S. Ahadian, N. Ashammakhi, M. R. Dokmeci, J.
864 Lee, A. Khademhosseini, *Adv. Healthc. Mater.* **2019**, 8, 1901379.
- 865 [49] A. Panwar, L. P. Tan, *Molecules* **2016**, 21.
- 866 [50] V. H. Mouser, F. P. Melchels, J. Visser, W. J. Dhert, D. Gawlitta, J. Malda,
867 *Biofabrication* **2016**, 8, 035003.
- 868 [51] N. Paxton, W. Smolan, T. Bock, F. Melchels, J. Groll, T. Jungst, *Biofabrication*
869 **2017**, 9, 044107.
- 870 [52] J. Yin, M. Yan, Y. Wang, J. Fu, H. Suo, *ACS Appl. Mater. Interfaces* **2018**, 10,
871 6849.
- 872 [53] M. Radisic, J. Malda, E. Epping, W. Geng, R. Langer, G. Vunjak-Novakovic,
873 *Biotechnol. Bioeng.* **2006**, 93, 332.
- 874 [54] A. Tocchio, M. Tamplenizza, F. Martello, I. Gerges, E. Rossi, S. Argenti, S.
875 Rodighiero, W. Zhao, P. Milani, C. Lenardi, *Biomaterials* **2015**, 45, 124.
- 876 [55] S. Alimperti, T. Mirabella, V. Bajaj, W. Polacheck, D. M. Pirone, J. Duffield, J.
877 Eyckmans, R. K. Assoian, C. S. Chen, *Proc. Natl. Acad. Sci. USA* **2017**, 114,
878 8758.
- 879 [56] D. Wei, W. Xiao, J. Sun, M. Zhong, L. Guo, H. Fan, X. Zhang, *J Mater. Chem.*
880 *B* **2015**, 3, 2753.
- 881

882 **The Table of Contents:**

883 The 3D printing engineering method reported in this article fabricated
884 centimeter-scale vascularized soft tissues with high viability and accuracy using
885 multi-materials bioprinting. It allowed us to fabricate vascular networks in
886 centimeter-scale hepatic tissues with active tissue functionality *in vitro* and *in vivo*,
887 which will potentially provide a model for fundamental drug screening studies.

888

